Retatrutide + Cagrilintide
Retatrutide + Cagrilintide
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, studied in Phase 2/3 obesity and MASLD trials with weight-loss results exceeding single/dual agonists. Paired here with cagrilintide (long-acting amylin receptor agonist) for combined appetite/metabolic research.
$ 118
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Retatrutide has not completed Phase 3 trials or received FDA approval as of mid-2026.
